Lead Product(s) : Gemfibrozil
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
US FDA Grants Orphan Drug Designation to Polaryx Therapeutics’ PLX-200 to Treat GM2 Gangliosidoses
Details : PLX-200 is a repurposed drug that binds to the retinoid X receptor-α (RXRα), which binds to PPARα. PLX-200 also activates PPARα, which enhances production of transcription factor EB (TFEB).
Brand Name : PLX-200
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 30, 2021
Lead Product(s) : Gemfibrozil
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
